SMARCB1 and neoplasm: Considering classifications with a calibrated score between 0.3 and 0.9, seven (77.8%) of the MFS samples were classified as “undifferentiated sarcoma” and two (22.2%; one tumor was a local recurrence in the same patient) were classified as “epithelioid sarcoma” (immunohistochemistry performed in these two cases demonstrated intact INI1 (SMARCB1) staining).